Exploratory Product Development Brief (EPDB) MCQs With Answer

Exploratory Product Development Brief (EPDB) MCQs With Answer

Introduction: The Exploratory Product Development Brief (EPDB) is a concise, strategic document used in early pharmaceutical development to capture the product concept, scientific rationale, high-level formulation and CMC considerations, regulatory pathway options, risk assessment, and go/no‑go criteria. For M.Pharm students specializing in Documentation & Regulatory Writing, mastering EPDB content is essential because it links discovery to development, aligns cross‑functional teams, and informs decision making for resource allocation and timelines. This quiz set emphasizes practical understanding of EPDB structure, critical quality attributes, regulatory implications, and development planning to prepare students for real‑world dossier and project initiation tasks.

Q1. What is the primary purpose of an Exploratory Product Development Brief (EPDB)?

• To serve as a final regulatory submission document
• To provide a high‑level roadmap for early product development, aligning scientific, CMC and regulatory strategy
• To replace the clinical trial protocol
• To present manufacturing batch records for commercialization

Correct Answer: To provide a high‑level roadmap for early product development, aligning scientific, CMC and regulatory strategy

Q2. Which of the following is NOT typically included in an EPDB?

• Target product profile and intended indications
• Preliminary formulation and analytical strategy
• Complete, detailed Phase III clinical trial protocol
• High‑level regulatory pathway options

Correct Answer: Complete, detailed Phase III clinical trial protocol

Q3. In the EPDB context, what does TPP stand for?

• Therapeutic Product Plan
• Target Product Profile
• Technology Preparation Protocol
• Testing and Performance Plan

Correct Answer: Target Product Profile

Q4. Which section of the EPDB directly addresses Critical Quality Attributes (CQAs)?

• Commercial pricing strategy
• Manufacturing site selection
• Product quality and CMC considerations
• Marketing and sales forecast

Correct Answer: Product quality and CMC considerations

Q5. Which risk management approach is typically outlined in an EPDB?

• Detailed corrective and preventive action (CAPA) logs for past batches
• High‑level risk assessment with mitigation strategies for formulation, stability and regulatory risks
• Final release specifications
• Full validation protocols for commercial manufacturing

Correct Answer: High‑level risk assessment with mitigation strategies for formulation, stability and regulatory risks

Q6. Which regulatory pathway consideration is appropriate to include in an EPDB?

• Definitive FDA approval letter
• Preliminary evaluation of potential pathways (e.g., full NDA, 505(b)(2), ANDA) and required studies
• Final labeling text approved by regulators
• Completed pediatric investigation plan

Correct Answer: Preliminary evaluation of potential pathways (e.g., full NDA, 505(b)(2), ANDA) and required studies

Q7. Which milestone is commonly defined in the EPDB timeline?

• Post‑market surveillance report due date
• Final commercialization launch party
• Go/no‑go decision points for lead formulation selection and first‑in‑human dosing
• Detailed GMP batch campaign schedule for year five

Correct Answer: Go/no‑go decision points for lead formulation selection and first‑in‑human dosing

Q8. At which stage of drug development is an EPDB usually prepared?

• Late post‑marketing phase
• Early product development, bridging discovery to preclinical and first‑in‑human planning
• Commercial production scale‑up only
• After regulatory approval for market launch

Correct Answer: Early product development, bridging discovery to preclinical and first‑in‑human planning

Q9. What type of analytical method information is expected in an EPDB?

• Fully validated stability indicating assay with validation reports
• High‑level list of required analytical capabilities and preliminary methods to assess identity, potency, purity and stability
• Only clinical bioassay protocols for Phase III
• Manufacturing in‑process control SOPs for commercial batches

Correct Answer: High‑level list of required analytical capabilities and preliminary methods to assess identity, potency, purity and stability

Q10. Which output of the EPDB directly informs early formulation strategy?

• Definitive commercial packaging artwork
• Selection of dosage form, route of administration, and excipient classes for prototype development
• Final validated analytical method SOPs
• Completed clinical safety database

Correct Answer: Selection of dosage form, route of administration, and excipient classes for prototype development

Q11. Which ICH guideline is most relevant when discussing pharmaceutical development content in an EPDB?

• ICH Q1A Stability
• ICH Q8 Pharmaceutical Development
• ICH M4 Common Technical Document (CTD) Module 5
• ICH Q3A Impurities in New Drug Substances

Correct Answer: ICH Q8 Pharmaceutical Development

Q12. Why is an intellectual property (IP) and freedom‑to‑operate (FTO) assessment included in an EPDB?

• To provide final patent prosecution documents
• To identify potential patent barriers and guide formulation or indication strategies to avoid infringement
• To replace regulatory submissions with patent filings
• To publish the product concept immediately

Correct Answer: To identify potential patent barriers and guide formulation or indication strategies to avoid infringement

Q13. What is the appropriate stability planning detail for an EPDB?

• Complete 3‑year real‑time stability dataset for commercial registration
• Preliminary stability study design including proposed storage conditions, timepoints and acceptance criteria for early prototypes
• Only photostability testing results for marketed product
• Full regulatory stability submission package

Correct Answer: Preliminary stability study design including proposed storage conditions, timepoints and acceptance criteria for early prototypes

Q14. Which of the following is NOT a typical CMC consideration documented in an EPDB?

• Preliminary formulation approach and excipient choices
• Planned analytical strategy and control strategy
• Clinical efficacy endpoints and statistical analysis plan
• High‑level manufacturing and scale‑up considerations

Correct Answer: Clinical efficacy endpoints and statistical analysis plan

Q15. Who are the primary stakeholders that should review and contribute to an EPDB?

• Only the discovery chemistry team
• Cross‑functional team including CMC, regulatory affairs, clinical development, quality assurance and manufacturing
• External marketing agencies only
• Only patent attorneys

Correct Answer: Cross‑functional team including CMC, regulatory affairs, clinical development, quality assurance and manufacturing

Q16. How does the EPDB assist in resource and budget planning?

• By providing exact future sales figures
• By outlining required technical activities, timelines and key resources to estimate costs and staffing needs
• By detailing final commercial production costs
• By replacing the need for a full project plan

Correct Answer: By outlining required technical activities, timelines and key resources to estimate costs and staffing needs

Q17. Which example represents an appropriate go/no‑go criterion included in an EPDB?

• Market share target for year five
• Failure to meet pre‑defined acceptable impurity limits or inability to achieve target potency in prototypes
• Final marketing approval by regulator
• Selection of sales representatives

Correct Answer: Failure to meet pre‑defined acceptable impurity limits or inability to achieve target potency in prototypes

Q18. What is the EPDB’s role regarding bioavailability and biopharmaceutics assessment?

• To provide full bioequivalence study reports
• To outline planned in vitro and early in vivo studies (e.g., solubility, permeability, pilot PK) to inform formulation choices
• To finalize commercial fed/fasted labeling
• To eliminate the need for pharmacokinetic testing

Correct Answer: To outline planned in vitro and early in vivo studies (e.g., solubility, permeability, pilot PK) to inform formulation choices

Q19. How are Quality by Design (QbD) concepts reflected in an EPDB?

• QbD is not relevant at EPDB stage
• By defining CQAs, identifying critical process parameters and proposing a design space and control strategy at a high level
• By providing final validated design space ready for filing
• By focusing solely on marketing aspects

Correct Answer: By defining CQAs, identifying critical process parameters and proposing a design space and control strategy at a high level

Q20. Which statement best describes the status of an EPDB in the product development lifecycle?

• The EPDB is the binding regulatory dossier submitted for approval
• The EPDB is an exploratory, living document used to inform early decisions and is refined as data accrues
• The EPDB is only used after commercialization
• The EPDB contains final validated commercial batch records

Correct Answer: The EPDB is an exploratory, living document used to inform early decisions and is refined as data accrues

Download